Renee Aguiar-Lucander
Renee Aguiar-Lucander
Chief Executive Officer
VIEW BIO
Renee Aguiar-Lucander
Renee Aguiar-Lucander
Chief Executive Officer

Born 1962. CEO since 2017.

Education: BA in Finance from Stockholm School of Economics. MBA from INSEAD.

Experience: Before joining Calliditas, Renée Aguiar-Lucander was a Partner and COO of Omega Fund Management, an international venture capital company focused on investments within the life science sector. Before that, she served as a Partner in the venture capital group 3i Group plc in London, where she managed the publicly quoted assets and was co-head of the global healthcare and technology portfolio. Prior to this, Renée Aguiar-Lucander was the European Group Head and Managing Director at a global investment bank and has more than 12 years’ experience in corporate finance. Prior to her career in investment banking, she was the Head of European Sales and Marketing in a company focused on the sale of software for financial services.

Other current assignments: Chairman of the board of directors of Exenta Inc. Member of the board of directors of Medcap AB (publ) and RAL Capital Ltd.

Holdings in the Company: Renée Aguiar-Lucander holds 412,000 shares in the Company, 545,000 warrants1 and 225,000 options2.

Frank Bringstrup
Frank Bringstrup
Vice President Regulatory Affairs
VIEW BIO
Frank Bringstrup
Frank Bringstrup
Vice President Regulatory Affairs

Born 1959. VP Regulatory Affairs since 2019.

Education: Medical education from the University of Copenhagen. He has a diploma in Managing Medical Product Innovation (MMPI) from the Copenhagen School of Economics, a diploma in business administration from Warwick University, and a post graduate specialist course in public health science from the National Board of Health, Denmark.

Experience: Frank Bringstrup has over 17 years of experience in the pharmaceutical industry within regulatory affairs and health authority interactions. Prior to joining Calliditas, he worked in various positions at Novo Nordisk A / S. He started his professional career first as a clinic doctor and then Frederiksborg County Medical Advisor.

Holding in the Company: Frank Bringstrup holds 12,500 warrants1 and 45,000 options2.

Fredrik Johansson
Fredrik Johansson
Chief Financial Officer
VIEW BIO
Fredrik Johansson
Fredrik Johansson
Chief Financial Officer

Born 1977. CFO since 2017.

Education: Studies in Business Law at Jönköping International Business School. Studies in Business and American law, Economics and Finance at Georgia State University, University of South Carolina and Lund University.

Experience: Fredrik Johansson has extensive experience in executive positions, primarily within telecom and software. Previously, he was CFO and COO at Birdstep Technology/ Techstep ASA, listed on the Oslo Stock Exchange, where he, among other things, was in charge of the acquisition and reversed listing of Teki Solutions. Previous CFO positions also include Phone Family, Teligent Telecom and Wayfinder Systems.

Other current assignments: Chairman of the board of directors of Truference AB. Holder of Fountainpark Consulting.

Holdings in the Company: Fredrik Johansson holds 88,250 shares in the Company, 140,000 warrants1 and 100,000 options2.

Richard Philipson
Richard Philipson
Chief Medical Officer
VIEW BIO
Richard Philipson
Richard Philipson
Chief Medical Officer

Born 1964. Chief Medical Officer since 2020.

Education: BSc in Biomedical Sciences at London University and MB MS, Middlesex Hospital Medical School. Member of the Royal College of Physicians and Fellow of the Faculty of Pharmaceutical Medicine.

Experience: Dr. Richard Philipson is a physician with 24 years of experience in the pharmaceutical industry from both large pharmaceutical companies and smaller biotechs. He has extensive experience in rare diseases, having brought several products from early development to the market. Prior to joining Calliditas, Richard worked as CMO with the UK-based biotech company Trizell where he led the Adstiladrin® phase 3 clinical program and Biologics License Application in non-muscle invasive bladder cancer, submitted to the FDA in September 2019. Before Trizell, he worked for Takeda as an Executive Medical Director and spent 16 years at GlaxoSmithKline, where he held a number of senior positions, including Disease Area Head and Acting Chief Medical Officer for the Rare Diseases Unit.

Before joining the industry, Richard worked as a physician in several clinical positions with various patient populations, including patients with IgA nephropathy.

Holding in the Company: 125,000 options.

Andrew Udell
Andrew Udell
Head of North America, Commercial
VIEW BIO
Andrew Udell
Andrew Udell
Head of North America, Commercial

Born 1970. Head of North America, Commercial since 2020. 

Education: BSc from Lehigh University. MBA from the University of Connecticut

Experience: Andrew Udell has more than 20 years of commercial experience in the pharmaceutical industry. Before joining Calliditas, Andrew worked as Vice President of North America Commercial at NeuroDerm. Andrew began his career in the pharmaceutical industry at Purdue Pharma and held several sales and marketing positions, including responsible for the company’s brands and led a multifunctional team for a multi-billion pain medication franchise.

Holding in the Company: Andrew Udell holds 220,000 warrants1 and 100,000 options2.

Katayoun Welin-Berger
Katayoun Welin-Berger
Vice President Operations
VIEW BIO
Katayoun Welin-Berger
Katayoun Welin-Berger
Vice President Operations

Born 1968. VP Operations since 2020.

Education: PhD in Pharmacy from Uppsala University, Sweden.

Experience: Katayoun Welin-Berger has more than 28 years of commercial experience in the pharmaceutical and biologics industry. Before joining Calliditas, Katayoun worked as Vice President of Operations at BioGaia. Katayoun began her career in the pharmaceutical industry at AstraZeneca and held several positions within both R&D and Operations.

Holding in the Company: Katayoun Welin-Berger holds 65,000 warrants1 and 45,000 options2.

Shareholding in the Company as of July 15, 2020.

Holding in Warrant program 2018/2022 and/or Warrant program 2019/2022.

Holding in ESOP 2020.

For more information on the warrants, see section Remuneration.